Open AccessArticle
The Public Health Impact of Coccidioidomycosis in Arizona and California
by
Richard F. Hector 1,*, George W. Rutherford 1, Clarisse A. Tsang 2, Laura M. Erhart 2, Orion McCotter 2, Shoana M. Anderson 2, Kenneth Komatsu 2, Farzaneh Tabnak 3, Duc J. Vugia 3, Ying Yang 3 and John N. Galgiani 4
1
Global Health Sciences, University of California, San Francisco (UCSF),1200 Beale St., #1200, San Francisco, CA 94105, USA
2
Arizona Department of Health Services, 150 N 18th Ave., Ste. 140, Phoenix, AZ 85007, USA
3
Infectious Diseases Branch, Division of Communicable Disease Control (DCDC), Center for Infectious Diseases (CID), California Department of Public Health, P.O. Box 997377, Sacramento, CA 95899, USA
4
Valley Fever Center for Excellence, College of Medicine, The University of Arizona, 1656 E. Mabel Street, Tucson, AZ 85724, USA
Cited by 99 | Viewed by 17215
Abstract
The numbers of reported cases of coccidioidomycosis in Arizona and California have risen dramatically over the past decade, with a 97.8% and 91.1% increase in incidence rates from 2001 to 2006 in the two states, respectively. Of those cases with reported race/ethnicity information,
[...] Read more.
The numbers of reported cases of coccidioidomycosis in Arizona and California have risen dramatically over the past decade, with a 97.8% and 91.1% increase in incidence rates from 2001 to 2006 in the two states, respectively. Of those cases with reported race/ethnicity information, Black/African Americans in Arizona and Hispanics and African/Americans in California experienced a disproportionately higher frequency of disease compared to other racial/ethnic groups. Lack of early diagnosis continues to be a problem, particularly in suspect community-acquired pneumonia, underscoring the need for more rapid and sensitive tests. Similarly, the inability of currently available therapeutics to reduce the duration and morbidity of this disease underscores the need for improved therapeutics and a preventive vaccine.
Full article
►▼
Show Figures